ProCE Banner Activity

AMG 330 Bispecific T-Cell Engager in Patients With R/R Acute Myeloid Leukemia: Update of First-in-Human Dose-Escalation Trial

Slideset Download
Conference Coverage
AMG 330, a CD33- and CD3-targeted bispecific T-cell engager appears safe and tolerable in dose-escalation study in patients with R/R AML.

Released: June 02, 2020

Expiration: June 01, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono